Physician profile
Louis Wasserman
NPI 1871589689
$4,488.83
in general payments reported to CMS, 2019-2025
24 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,330 · 2020: $170 · 2021: $312 · 2022: $180 · 2023: $593 · 2024: $831 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,478 · Education: $19.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,477.54 |
| Education | $19.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $815.29 | 2019-2025 | |
| Abbott Laboratories | $707.14 | 2019-2025 | Aveir |
| Alnylam Pharmaceuticals INC. | $447.88 | 2019-2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $439.49 | 2019-2024 | Xarelto |
| Amgen INC. | $393.19 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $350.48 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.39 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $208.43 | 2023-2025 | Wainua, Farxiga |
| Kestra Medical Technology Services, INC. | $148.25 | 2023 | Assure Wcd |
| Bridgebio Pharma, INC. | $118.38 | 2025 | Attruby |
| Amarin Pharma, INC. | $93.45 | 2019-2021 | |
| Boston Scientific Corporation | $80.75 | 2022-2023 | Watchman Flx |
| Impulse Dynamics (USA) INC. | $66.39 | 2024 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $55.58 | 2025 | Camzyos |
| Novo Nordisk INC | $51.37 | 2025 | Wegovy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $41.98 | 2024 | Nexletol |
| Abiomed | $39.80 | 2024 | Impella |
| Philips North America LLC | $34.87 | 2024 | (Cm9) Amb Mon & Diag Und |
| Medtronic, INC. | $32.14 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.78 | 2022-2024 | Lifevest |
| Lilly USA, LLC | $30.71 | 2025 | Zepbound |
| Ge Healthcare | $24.33 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $19.13 | 2023 | Inpefa |
| Cvrx, INC. | $17.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.